Fused Pyrimidine-Based Drug Discovery

Erscheinungsjahr 2022
ISBN: 978-0-12-824531-6
Verlag: Elsevier Science

Buch, Englisch, 320 Seiten, Format (B × H): 152 mm x 229 mm

Reihe: Heterocyclic Drug Discovery

Fused Pyrimidine-Based Drug Discovery covers all categories of fused-pyrimidines along with pharmacological and in silico studies. It covers chemistry and biological activities, as well as the design of novel fused-pyrimidine scaffolds. N-Heterocyclic scaffolds are found in most known drug candidates and are of interest to medicinal and organic chemists to design, synthesize and evaluate their biological properties. A variety of fused-pyrimidine molecules have been synthesized and extracted from natural resources and are found to exhibit various biological activities such as antifolates, anticancer agents, analgesics, antimetabolites, CNS active agents, and many more.

This book focuses on nomenclature, structural chemistry, and chemical and physical properties, along with various approaches for their synthesis. It is ideal for researchers in organic chemistry, both in academic and industrial settings and for postgraduates in chemistry and medicinal chemistry.


- Features synthetic schemes, approaches and strategies for fused pyrimidine scaffolds
- Includes new fused-pyrimidine scaffolds, allowing the researcher to predict the mechanisms involved in their synthesis
- Covers in silico studies of known fused pyrimidines and Structure Activity Relationship (SAR) that encourage the development of new or modified existing scaffolds with specific biological activities

Zielgruppe

<p>Primary: Researchers in organic chemistry both in academic and industrial settings, postgraduates in chemistry and medicinal chemistry.</p> <p>Secondary: Researchers in pharmaceutical industries, chemical and pesticide industries.</p>

Autoren/Hrsg.

Kumar, Raj

Fachgebiete

• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Naturwissenschaften Chemie Organische Chemie

Inhaltsverzeichnis

1. Introduction
2. FDA Approved Fused Pyrimidine-Based Drugs
3. Five-Membered Ring Fused Pyrimidine-Based Derivatives (eg. purines) and Biological Properties
4. Six- Membered Ring Fused Pyrimidine-Based Derivatives (eg. Quinazolines, pteridines) and Biological Properties
5. Seven-Membered Ring Fused Pyrimidine-Based Derivatives and Biological Properties
6. Eight-Membered Fused Pyrimidine Derivatives (eg. azocine) and Biological Properties
7. Naturally occurring fused pyrimidine derivatives and Medicinal Attributes
8. Molecular Modeling Studies of Fused Pyrimidine Derivatives at various receptors

Über Autor(innen)

Kumar, Raj
Raj Kumar Ph.D. is a Professor of Organic Medicinal Chemistry at Central University of Punjab, Bathinda, India 151001. He obtained his Ph.D. in Medicinal Chemistry (2007) from NIPER, Mohali, India and completed his postdoctoral fellowship (2007-2008) at the University of Maryland Baltimore County (UMBC), Maryland where he coinvented a fused heterocycle RK-33 (Raj Kumar-33) molecule for the treatment of Lung Cancer. His research interests focus on the design and synthesis of novel fused heterocycles of biological importance.